The retatrutide trial record — mechanism, endpoints, and what Phase 3 must confirm.

The brief version

This page reviews the published science on retatrutide — an investigational compound, not an approved drug — developed by Eli Lilly and in Phase 3 trials as of 2026. The key question the research addresses is whether simultaneously activating three metabolic hormone receptors produces more weight loss and better metabolic outcomes than activating one or two.

Phase 2 data say yes, by a substantial margin. The obesity trial measured a mean 24.2% body-weight reduction at the highest dose over 48 weeks. The liver-MASLD substudy found that 86% of participants reached normal liver-fat levels by week 24. The type 2 diabetes trial showed HbA1c — the standard blood-sugar control marker — falling 2.02 percentage points.

These are the most relevant numbers. What follows is the mechanism that explains them, the trials that measured them, and the questions that Phase 3 is designed to answer. Every quantitative claim is cited to its source study.

Triple-agonist mechanism: why three receptors matter

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide engineered to activate three class-B G-protein-coupled receptors (GPCRs — cell-surface receptors that transmit hormonal signals into the cell) simultaneously: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR).

The GLP-1 arm suppresses appetite via hypothalamic (brain hunger-center) signaling and slows gastric emptying, extending the physical sense of fullness. It also triggers glucose-dependent insulin secretion — meaning insulin release is amplified only when blood glucose is elevated, reducing hypoglycemia risk compared with older insulin-based agents.

The GIP arm further enhances postprandial (after-meal) insulin secretion and has adipose (fat-tissue) remodeling effects. Its role in combination therapy appears synergistic with GLP-1: the dual incretin activation produces larger appetite and insulin effects than either alone.

The glucagon arm is what separates retatrutide from dual GLP-1/GIP agonists. Glucagon receptor activation raises energy expenditure — the body burns more calories at rest — and drives hepatic lipolysis (liver fat breakdown) and mitochondrial fat oxidation in the liver. This hepatic pathway is the mechanistic basis for retatrutide's striking MASLD results ^[7].

Cryo-EM structural analysis confirmed retatrutide engages all three receptors, with measured relative potency of approximately 8.9× native GIP at GIPR, 0.3× at GCGR, and 0.4× at GLP-1R versus the respective endogenous hormones ^[3]. The GIP-dominant design reflects intentional balancing: high GIP potency maximizes insulinotropic and adipose effect without over-driving the more potent GLP-1 axis.

The liver-MASLD lens: the strongest finding in this dossier

MASLD (metabolic dysfunction-associated steatotic liver disease — the current term for fatty liver tied to metabolic syndrome, formerly called NAFLD) represents the lens most relevant to retatrutide results tracked on this site.

The dedicated Phase 2a MASLD substudy enrolled 98 participants with obesity or overweight, at least 10% liver fat by MRI-PDFF (magnetic resonance imaging proton density fat fraction — the standard non-invasive liver-fat measurement), and no type 2 diabetes. Liver fat reduction at 24 weeks was dose-dependent: −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg) versus +0.3% with placebo. At 12 mg, 86% of participants achieved normal liver fat (below 5%) by week 24 — reductions maintained to −86.0% at 48 weeks ^[5].

A 2026 network meta-analysis across 6 RCTs found glucagon receptor agonists (including retatrutide) significantly reduced MRI-PDFF with a mean difference of −46.09 and ALT (alanine aminotransferase, a liver enzyme elevated by liver injury) by −22.10, while also significantly decreasing ELF (enhanced liver fibrosis) scores ^[12]. A parallel network meta-analysis ranked retatrutide highest among anti-obesity medications for weight and HbA1c reduction versus placebo — the only agent whose HbA1c effect reached significance in that analysis ^[14].

The mechanistic review literature confirms the pathway: glucagon receptor activation stimulates hepatic lipolysis and mitochondrial fat oxidation; GLP-1/GIP agonism reduces caloric intake and systemic fat mass; the combination drives more liver-fat clearance than either approach alone ^[7][13].

Retatrutide has been characterized as producing the most pronounced metabolic effects to date among anti-obesity medications tested in MASLD, though its direct impact on liver histology (tissue biopsy-level fibrosis scoring) remains underexplored, and the authors of one 2025 review note that advanced MASLD may alter its pharmacokinetics ^[8].

Phase 2 obesity and type 2 diabetes trials

Obesity (Phase 2, 48 weeks, NEJM 2023 ^[1]): 338 adults, doses 1/4/8/12 mg once weekly subcutaneous injection. Mean body-weight change at 48 weeks: −24.2% at 12 mg versus −2.1% placebo. GI adverse events were dose-related and mostly mild-to-moderate. Dose-dependent heart-rate increase peaked at 24 weeks.

Type 2 diabetes (Phase 2, 36 weeks, Lancet 2023 ^[2]): 281 adults, doses 0.5–12 mg once weekly with stepwise escalation. HbA1c: −2.02 percentage points (12 mg) versus −0.01 (placebo) at 24 weeks. Body weight: −16.94% versus −3.00% placebo at 36 weeks. Mild-to-moderate GI AEs in 35%; no severe hypoglycemia; no deaths.

First-in-human Phase 1b (Lancet 2022 ^[4]): 72 adults with type 2 diabetes, dose escalation 0.5–12 mg once weekly over 12 weeks. Half-life confirmed approximately 6 days, supporting once-weekly dosing. Placebo-adjusted weight loss −8.96 kg (90% CI −11.16 to −6.75) at highest dose. Daily mean glucose −2.8 mmol/L at 3 mg. Acceptable safety profile established.

Retatrutide vs tirzepatide

No head-to-head trial between retatrutide and tirzepatide has been published. The systematic review by Moiz et al. (2025) that scanned 26 RCTs in 15,491 adults found retatrutide 12 mg reported the largest single weight-loss figure (22.1%, 95% CI 19.3%–24.9% at 48 weeks) among agents evaluated, versus tirzepatide 15 mg at 17.8% at 72 weeks and semaglutide 2.4 mg at 13.9% at 68 weeks ^[9]. The comparison is descriptive — no meta-analysis was possible due to heterogeneity in populations, trial durations, and baseline characteristics. The ongoing TRIUMPH active-comparator trial is designed to provide a direct comparison of retatrutide versus tirzepatide.

A 2025 review (Katsi et al., Biomolecules) characterized the up-to-~24% weight loss seen in retatrutide Phase 1/2 trials as a step-change versus prior incretin therapies, based on aggregate synthesis of the trial data ^[6].

Phase 3: TRIUMPH and open questions

The TRIUMPH program (Eli Lilly's Phase 3 retatrutide portfolio as of mid-2026) includes:

• TRIUMPH-1 and TRIUMPH-2: obesity endpoints, large enrollment, 52+ weeks
• TRIUMPH-3: type 2 diabetes glycemic and weight endpoints
• NCT06383390: dedicated cardiovascular outcomes trial
• NCT05929066 and NCT05931367: CKD (chronic kidney disease) and cardiac safety
• TRANSCEND-CKD: renal-focused safety study

Open questions the trials are designed to address: long-term durability of weight loss; whether weight regain after discontinuation mirrors what the GLP-1 class shows; cardiovascular outcomes (MACE — major adverse cardiac events); renal safety at scale; and whether the MASLD liver-histology improvements translate into reduced fibrosis progression.

A 2025 Annual Review paper noted that weight rebound after cessation remains a class-level challenge for unimolecular polypharmacology agents including retatrutide, and that continued innovation is needed for durable outcomes ^[10]. A 2026 review framed anti-obesity therapy failure as multifactorial — including post-treatment weight regain, pharmacogenomic response variation, and anti-drug antibody development — and noted that real-world outcomes frequently diverge from trial efficacy ^[11].

Recent literature: 2024–2026

**Abenavoli et al. (2026), Medicina.** Potent hepatoprotective effects and favorable metabolic remodeling in MASLD; benefits on fibrosis progression noted as limited but promising in the current evidence base ^[11].

**Andonie et al. (2026), Endocrinology, Diabetes & Metabolism.** Network meta-analysis of glucagon receptor agonists versus resmetirom in MASLD: MRI-PDFF mean difference −46.09, ALT −22.10, significant ELF score reduction with GRAs; resmetirom superior for MASH resolution without worsening fibrosis ^[12].

**Lu et al. (2026), Frontiers in Medicine.** Mechanistic review covering hepatic lipid metabolism regulation, anti-inflammatory effects, and fibrosis modulation for GLP-1/GIP/glucagon triple agonism in MASLD ^[13].

**Abulehia et al. (2026), Endocrinology, Diabetes & Metabolism.** Network meta-analysis: retatrutide ranked highest for weight and HbA1c reduction versus placebo among glucagon receptor agonists; only retatrutide's HbA1c effect reached significance; survodutide second; head-to-head trials needed ^[14].

See Retatrutide references for the full citation list.